French Govt Calls For 70% Biosimilar Prescribing Rate; Substitution Groups Published
Executive Summary
Moves are under way in France to give the biosimilars market a shot in the arm by setting a 70% target for initial prescribing rates and encouraging pharmacist substitution through the creation of similar biological medicine groups.
You may also be interested in...
French Doctors “Struggling” With Biosimilar Switching
Doctors in the Paris hospital network are struggling with issues such as biosimilar switching and procurement.
French Doctors “Struggling” With Biosimilar Switching
Doctors in the Paris hospital network are struggling with issues such as biosimilar switching and procurement.
France Relaxes Stance On Biosimilar Switching
The French regulatory agency ANSM has relaxed its stance on biosimilar interchangeability to state that while in principle patients should preferably not be switched between a reference drug and a biosimilar during their course of treatment, this can be done provided the patient agrees and their treatment is closely monitored1.